The backup bidder to Regeneron is a nonprofit apparently started by former 23andMe CEO Anne Wojcicki. Meet the company that ...

The demand for the widely used cancer drug Taxol is increasing, but it's difficult and expensive to produce because it hasn't been possible to do it biosynthetically. Until now, that is. Researchers ...

Global pharmaceutical giant Eli Lilly & Co. is seeking tax incentives for a potential 236-acre biomanufacturing plant in ...

AmplifyBio said in a statement April 4, saying the decision to close followed months of efforts to keep the four-year-old ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Story April 14 - Third Harmonic Bio: The California biotech has abandoned plans to take its chronic spontaneous urticaria drug into phase ... Cherokee manufacturing plant in Riverside ...

Deputy Minister of Health Do Xuan Tuyen concluded a six-day visit to Cuba on May 22, aimed at strengthening bilateral ...

Microalgae of the species Monoraphidium contortum have the ability to remove antibiotic residues from water, especially ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

AmplifyBio faces a lawsuit for allegedly violating layoff notification laws after closing its central Ohio facilities on April 4.